Insulin developers from Sverdlovsk will receive 183 million roubles to expand their production. Almost 200 million roubles will be invested in the insulin production in the Urals. The money will be allocated by the Industry Development Fund. The loan will be directed to the expansion of the first biopharmaceutical import-substituting production of genetically engineered insulin.

The implementation of the project will make it possible to abandon purchasing the substance abroad and to develop domestic production at the Novouralsk Biomedical Technopark. This will help reduce the price of finished insulin by 15-20% relative to the imported one.

The medicine will be produced in the most convenient and familiar forms for patients: in cartridges and syringe pens. The latter, by the way, will be presented at the INNOPROM 2016 international industrial exhibition. Medsintez's project was included in the federal support list thanks to the active participation of the regional Ministry of Industry and Science.